Ple Na es we dJ oo u nr no at l ao df jCu hs et mm i as tr rgy ins
Page 10 of 13
ARTICLE
Journal Name
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
Furthermore, we studied the anti-mycobacterial activity and docking
correlations of the synthesized complexes. The complexes were
found to be active against Mtb and β-CD/HBIH showed better activity
compared to isoniazid inclusion complex. These complexes open a
new door in anti-TB drug design perspective by providing highly
specific, non-toxic candidates. Given the easy preparation and
environmentally friendly process for inclusion complexes, it is a
promising way to design novel prototypes of isoniazid congeners
with excellent water solubility and bioavailability for future
pharmaceutical applications.
D. Sarkar, S. P. Chavan and H. B. BorateD, EOuIr:.1J0..M10e3d9./CCh9eNmJ.0,62305117J,
1
27, 459-469.
1
1
5. A. Kajal, S. Bala, S. Kamboj, N. Sharma and V. Saini, J. Catal, Article
ID 893512, 2013, 1–14.
6. M. J. Hearn, M. H. Cynamon, M. F. Chen, R. Coppins, J. Davis, H.
Joo-On Kang, A. Noble, B. Tu-Sekine, M. S. Terrot, D.
Trombino, M.Thai, E.R. Webster and R. Wilson Eur. J. Med. Chem.,
2009, 4(10), 4169–4178.
17. P. Dandawate, K. Vemuri, K. V. Swamy, E. M. Khan, M. Sritharan,
and S. Padhye, Bioorg. Med. Chem. Lett., 2014, 24, 5070–5075.
18. R. Karwal, T. Garg, G. Rath and T.S. Markandeywar, Ther. Drug
Carrier Syst., 2016, 33, 1–39.
9. Y. Wei, J. Zhang, Y. Zhou, W. Bei, Y. Li, Q. Yuan and H. Liang,
Carbohydr. Polym., 2017, 159, 152-160.
0. M. Gallo, A. Favilla and D.G. Mitnik, Chem. Phys. Lett. 2007, 447,
105-109.
1. N. Saikia and R.C. Deka. Chem. Phys. Lett. 2010, 500, 65–70.
2. N Saikia, S Rajkhowa, R.C. Deka. RSC Advances 2016, 6, 94651-
4660.
3. D. Kumar,Y. Krishnan, M. Paranjothy and S. Pal, J. Phys. Chem. B,
017, 121, 2864-2872.
4. N. Qiu, X. Zhao, Q. Liu, B. Shen, J. Liu, X. Li and L. An, J. Mol. Liq.,
019, 289, 111151- 111161.
25. S. Gao, C. Bie, Q. Ji, H. Ling, C. Li, Y. Fu, L. Zhao, and F. Ye, RSC Adv.,
2019, 9, 26109–26115.
26. S. Mohandoss, R. Atchudan, T. N. Jebakumar, I. Edison, T. K.
Mandal, S. Palanisamy, S. G. You, A. A. Napoleon, J. Shim and Y. R.
Lee, Carbohydr. Polym., 2019, 224, 115166-115176.
7. G. Liu, Q. Yuan, G. Hollett, W. Zhao, Y. Kang and J. Wu, Polym.
Chem., 2018, 9(25), 3436–3449.
8. S. V. Kurkov and T. Loftsson, Int. J. Pharm., 2013, 453, 167–180.
9. Z. Ren, Y. Xu, Z. Lu, Z. Wang, C. Chen, Y. Guo, X. Shi, F. Li, J. Yang
and Y. Zheng, RSC Adv., 2019, 9, 11396–11405.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
Conflicts of interest
1
“
There are no conflicts to declare”.
2
Acknowledgements
2
2
Lincy Tom gratefully acknowledges CSIR, New Delhi, India for
financial support in the form of a Senior Research Fellowship. The
authors are thankful to the Sophisticated Analytical Instrumentation
Facility (SAIF), Kochi and IIT madras for SEM, PXRD and NMR studies.
We thank National Institute for Research in Tuberculosis, Chennai for
anti-TB studies. We also thank Biogenix Research center,
Thiruvananthapuram for cell viability studies.
9
2
2
2
2
References
1
.
D.A Enarson and J. F Murray, Global Epidemiology of Tuberculosis.
In Tuberculosis; Rom, (W. N., Garay, S., Eds.), Little Brown and Co.:
Boston, 1996, pp 57–75.
World Health Organization, Global Tuberculosis Control, WHO
Report, 2018.
2
2
2
2
.
3. H. Jnawali and S. Ryoo, First- and second-line drugs and drug
resistance. Available at
3
3
0. V. B. Chaudhary and J. K. Patel, Int. J. Pharm. Sci. Res., 2013, 4(1),
6
8-76.
drug-resistance. 2013
1. T. Higuchi and K. A. Connors, Phase Solubility Techniques, Wiley
Interscience, New York, 1965.
2. M. F. Sanner, J. Mol. Graph. Model. 1999, 17, 57-61.
34. Dassault Systèmes BIOVIA, Discovery Studio Modeling
Environment, Release 2017, San Diego: Dassault Systèmes, 2016.
35. G. M.Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D.
S. Goodsell, and A. J. Olson, J. Comput. Chem., 2009, 16, 2785-91.
3
3
4
.
M. Gengenbacher and S. Kaufmann, FEMS Microbiol. Rev., 2012
3
6, 514–532.
5
6
.
.
H. Meyer and J. Mally, Monatsh, 1912, 33, 393-414.
S. P. Klemens, C.A. Sharpe and M. H. Cynamon, Antimicrob. Agents
7
8
.
.
3
6. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M.
Greenblatt, E. C. Meng and T. E. Ferrin, J. Comput. Chem., 2004,
J. Med., 1947, 2(5), 429–435.
2
5(13), 1605-1612.
3
7. W. R. Jacobs, R. G. Jr, Barletta, R. Udani, J. Chan, G. Kalkut, G.
9. A. J. J. Wood and M. D. Iseman, N. Engl. J. Med., 1993, 329 (11),
784–791.
10. S. Ramaswamy and J.M. Musser, Tuber. Lung Dis., 1998, 79(1), 3–
Sosne, G.J. Kieser, G.F. Hatfull, and B.R. Bloom, Science, 1993, 260,
8
19–822.
3
3
8. V. N. A. Dusthackeer, S. Balaji, N. S. Gomathi, N. Selvakumar and
V. Kumar, Clin. Microbiol. Infect., 2012, 18, 492–496.
9. V.B. Makane, V.S. Krishna, E.V. Krishna, M. Shukla, B. Mahizhaveni,
S. Misra, S. Chopra, D. Sriram, V.N.A. Dusthackeer and H.B. Rode,
Eur. J. Med. Chem., 2019, 164, 665-677.
40. L. B. Talarico, R. G. Zibetti, P. C. Faria, L. A. Scolaro, M. E. Duarte,
M. D. Nosed, C.A. Pujol, E.B. Damonte, Int. J. Biol. Macromol,
2004, 34, 63-71.
1. S. Tanwar, C. Barbey and N. Dupont, Carbohydr. Polym., 2019, 217,
6-34.
2
9.
1. A. Velayati, P. Farnia and M. Masjedi, Int. J. Clin. Exp. Med., 2013,
(4), 307–309.
2. R. Saha, M. M. Alam and M. Akhter, RSC Adv., 2015, 5(17), 12807-
2820.
1
1
1
6
1
3. R. Revathi, R. V.Perumal, K. S. R. Pai, G. Arunkumar, D. Sriram and
S. G. Kini, Drug Des., Devel. Ther., 2015, 9, 3779–3787.
4
2
1
0 | J. Name., 2012, 00, 1-3
This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins